Literature DB >> 9252692

MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21WAF1.

W Xie1, K Su, D Wang, A J Paterson, J E Kudlow.   

Abstract

Epidermal growth factor (EGF) usually stimulates the proliferation of a variety of normal and malignant cells. In contrast, MDA468, a human breast cancer cell line with a very high number of EGF receptors, is growth inhibited in response to concentrations of EGF that stimulate most other cells. The purpose of this study was to elucidate the cellular mechanisms involved in EGF-induced growth inhibition. EGF treatment stimulated the sustained expression of the cyclin-dependent kinase (CDK) inhibitor p21WAF1. The p21WAF1 induction in EGF-treated MDA468 cells is probably p53-independent since these cells contain no active p53. The promoter for p21WAF1 gene contains binding sites for signal transducer and activator of transcription (STAT) and EGF is known to activate members of this family of transcription factors. Using electrophoretic mobility shift assays (EMSA), we found that EGF activates STAT1 and STAT3 in the MDA468 cells. These activated STATs specifically recognized the three conserved STAT-responsive elements in the p21WAF1 gene promoter, suggesting that STATs may be responsible for the p21WAF1 induction by EGF in MDA468 cells. The sustained rise in p21WAF1 in response to EGF is proposed to be a means of growth inhibition in these cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252692

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis.

Authors:  R T Nitta; C A Del Vecchio; A H Chu; S S Mitra; A K Godwin; A J Wong
Journal:  Oncogene       Date:  2010-09-27       Impact factor: 9.867

2.  A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors.

Authors:  E C Piccione; T J Lieu; C F Gentile; T R Williams; A J Connolly; A K Godwin; A C Koong; A J Wong
Journal:  Oncogene       Date:  2011-10-10       Impact factor: 9.867

Review 3.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

4.  Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma.

Authors:  David A Schoenfeld; Royce Zhou; Sakellarios Zairis; William Su; Nicole Steinbach; Deepti Mathur; Ankita Bansal; Alexis L Zachem; Bertilia Tavarez; Dan Hasson; Emily Bernstein; Raul Rabadan; Ramon Parsons
Journal:  Mol Cancer Res       Date:  2022-08-05       Impact factor: 6.333

5.  Effects of epidermal growth factor and its signal transduction inhibitors on apoptosis in human colorectal cancer cells.

Authors:  Jane C J Chao; Wen Li Peng; Sheng-Hsuan Chen
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.